QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) An erratum has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lattard, V. Articles by Cashman, J. R. Search for Related Content PubMed PubMed Citation Articles by Lattard, V. Articles by Cashman, J. R.

TWO NEW POLYMORPHISMS OF THE FMO3 GENE IN CAUCASIAN AND AFRICAN-AMERICAN POPULATIONS: COMPARATIVE GENETIC AND FUNCTIONAL STUDIES

Human BioMolecular Research Institute, San Diego, California (V.L., J.Z., Q.T., J.R.C.); and Environmental Toxicology Program, University of California, Riverside, California (B.F., D.S.)

To characterize the contribution of the human flavin-containing monooxygenase form 3 (FMO3) in the metabolism and disposition of drugs and xenobiotics, we determined the single nucleotide polymorphisms in the coding region and adjacent splice junctions of FMO3 in 134 African Americans and 120 Caucasians from the United States. In the regions examined, DNA resequencing or high throughput MassEXTEND studies coupled with mass spectrometric genotyping showed that 12 sites of variation were present. Three variants encoding synonymous mutations and four polymorphisms were observed in the noncoding region. Another three variants, Lys¹⁵⁸-FMO3, Met²⁵⁷-FMO3 and Gly³⁰⁸-FMO3, previously reported in similar populations, were prominent polymorphisms. Two new polymorphisms, His¹³²-FMO3 and Pro³⁶⁰-FMO3, were identified in this study. Both variants were found only in African Americans. To evaluate the effect of the amino acid substitutions on the function of FMO3, each amino acid substitution was introduced by site-directed mutagenesis into a wild-type FMO3 cDNA. Selective functional activity was studied with methimazole, trimethylamine, and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl) phenothiazine. Both His¹³²-FMO3 and Pro³⁶⁰-FMO3 variants were able to metabolize the substrates examined. Compared with wild-type FMO3, the His¹³²-FMO3 was less catalytically efficient. The His¹³²-FMO3 variant moderately altered the catalytic efficiency of FMO3 (decrease of 30%, 60% and 6% with methimazole, trimethylamine and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine, respectively). The Pro³⁶⁰-FMO3 variant was more catalytically efficient than wild-type FMO3. Pro³⁶⁰-FMO3 oxygenated methimazole, trimethylamine and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine, respectively, 3-, 5- and 2-fold more efficiently than wild-type FMO3. Based on the functional activity of the variant FMO3 enzymes, it is likely that population differences exist for compounds primarily metabolized by FMO3.

This article has been cited by other articles:

				A. A. Francois, C. R. Nishida, P. R. O. de Montellano, I. R. Phillips, and E. A. Shephard Human Flavin-Containing Monooxygenase 2.1 Catalyzes Oxygenation of the Antitubercular Drugs Thiacetazone and Ethionamide Drug Metab. Dispos., January 1, 2009; 37(1): 178 - 186. [Abstract] [Full Text] [PDF]

				T. Borbas, J. Zhang, M. A. Cerny, I. Liko, and J. R. Cashman Investigation of Structure and Function of a Catalytically Efficient Variant of the Human Flavin-Containing Monooxygenase Form 3 Drug Metab. Dispos., December 1, 2006; 34(12): 1995 - 2002. [Abstract] [Full Text] [PDF]

				S. B. Koukouritaki, M. T. Poch, E. T. Cabacungan, D. G. McCarver, and R. N. Hines Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants Mol. Pharmacol., August 1, 2005; 68(2): 383 - 392. [Abstract] [Full Text] [PDF]

				I. M. Hisamuddin, M. A. Wehbi, A. Chao, H. W. Wyre, L. M. Hylind, F. M. Giardiello, and V. W. Yang Genetic Polymorphisms of Human Flavin Monooxygenase 3 in Sulindac-Mediated Primary Chemoprevention of Familial Adenomatous Polyposis Clin. Cancer Res., December 15, 2004; 10(24): 8357 - 8362. [Abstract] [Full Text] [PDF]

				B. Furnes and D. Schlenk Evaluation of Xenobiotic N- and S-Oxidation by Variant Flavin-Containing Monooxygenase 1 (FMO1) Enzymes Toxicol. Sci., April 1, 2004; 78(2): 196 - 203. [Abstract] [Full Text] [PDF]